Sentences with phrase «model of breast cancer»

Using a preclinical model of breast cancer, the researchers showed that anti-tumor cells placed via scaffold prevented relapse while intravenously administered T cells did not.

Putative model of breast cancer cell hierarchy and the hypoxic effect.

Robert D. Schreiber, Ph.D., an associate director of CRI's Scientific Advisory Council based at Washington University School of Medicine in Saint Louis, Missouri, developed a new model of breast cancer that more closely resembles the progression of hormone receptor - positive disease in humans, overcoming a major obstacle in the study of breast cancer and the development of new immune - based therapies for the disease.

Moreover, ablation of a STAT5A allele reduces tumor incidence in a mouse model of breast cancer in which mammary epithelial cells express T antigen (48).

T - cells (red, yellow, and blue) attack a tumour in a mouse model of breast cancer following treatment with radiation and a PD - L1 immune checkpoint inhibitor, as seen by transparent tumour tomography.

Therefore, we have explored the role of the alpha2 beta1 integrin in cancer initiation and progression using a clinically - relevant, spontaneous mouse model, the MMTV - Neu model of breast cancer progression and metastasis.

2) The two repeated experiments analyze the source of POSTN expression in the lung and whether it affects the number / size of primary and secondary tumor formation in a spontaneous mouse model of breast cancer (MMTV - PyMT).

From there, they used the preferred published model of breast cancer risk from radiation exposure to project the number of radiation - induced breast cancers.

Similar results were observed in a mouse model of breast cancer.

Then they removed the protein in a mouse model of breast cancer and discovered the cancer's ability to spread was significantly reduced.

When the team used the retinoid fenretinide along with anti-estrogen therapy in mouse models of breast cancer, they did not see the expansion of CK5 + cells previously seen with anti-estrogen therapy alone.

Working with human breast cancer cells and mouse models of breast cancer, scientists identified a new protein that plays a key role in reprogramming cancer cells to migrate and invade other organs.

«The result was an extensive inhibition of tumor growth and prevention of metastasis to the lung in HER2 - positive animal models of breast cancer,» notes Navasona Krishnan, Ph.D., a postdoctoral investigator in the Tonks lab who performed many of the experiments and is lead author on the paper reporting the results.

Working in mouse models of breast cancer and breast tumor samples from patients, Longmore and his colleagues showed that a protein that sits on the surface of tumor cells, called DDR2, binds to collagen and activates a multistep pathway that encourages tumor cells to spread.

Future studies will test and compare the efficacy of imatinib and allosteric compounds in mouse models of breast cancer.

Deletion of the amino acid transporter Slc6a14 suppresses tumour growth in spontaneous mouse models of breast cancer

In addition, we asked whether parity leads to persistent STAT5 activation in classical transgenic models of breast cancer.

Wayne State University — College of Engineering, Detroit • MI 4/2011 — 4/2012 Graduate Research Assistant Developed algorithms, simulations and processes for data collection to support modeling of breast cancer detection using optical spectroscopy.

Not exact matches

We modeled cases of breast cancer, premenopausal ovarian cancer, hypertension, type 2 diabetes mellitus, and myocardial infarction considering direct costs, indirect costs, and cost of premature death (before age 70 years) expressed in 2011 dollars.

The researchers tested their drug compound, Targapremir - 210, in mouse models of triple negative breast cancer.

Three - dimensional models of living tissue will advance understanding of human breast development as well as the growth of breast cancer.

For researchers using mouse models to study a variety of cancers, including lymphoma, melanoma, breast, and prostate cancers as well as autoimmune and infectious diseases, the panel facilitates a highly sensitive and high - throughput investigation of biomarkers associated with disease progression.

«Indeed, in a second tumor model of metastatic breast cancer, we demonstrated that mice treated with the EphA2 - targeting paclitaxel conjugate presented nearly no lung metastases, while a large numbers of lesions were observed in both untreated mice and in mice treated with just paclitaxel.»

Recent collaborative work between UCR and Cedars - Sinai Medical Center in Los Angeles demonstrated that in animal models of human breast cancer, mice treated with 123B9 that was conjugated with paclitaxel had significantly fewer circulating cancer cells in the blood compared to mice that were not treated or even treated with paclitaxel alone.

In the future, this model will be used to assess whether the clinical heterogeneity observed in breast cancers arises from their different cancer cell of origin.

In the Cell study, Dr. Massagué, with Fellow Manuel Valiente, PhD, and other team members, found that in mouse models of breast and lung cancer — two tumor types that often spread to the brain — many cancer cells that enter the brain are killed by astrocytes.

The research, conducted in cell lines and mouse models, explored enhancing the cancer - killing effects of PARP inhibitors not only in regard to AML but also triple - negative breast cancer.

Last January, state - of - the - art computer aided modeling enabled the researchers to identify an anti-cancer agent capable of deactivating a gene known to be essential for the metastatic spread of breast cancer.

The researchers observed the effect of the synthetically produced molecule, JK - 31, on the growth and proliferation of a model human breast cancer cell line and found that it effectively blocked the protein cyclin - dependent kinase 1 (CDK1), which plays a key part in the process of the division of cancer cells, and therefore inhibited the proliferation of the cells.

Its research includes a cluster of related interdisciplinary projects that examine disparities in breast cancer mortality between African - American and Caucasian women using animal models, molecular characterization of tumors, and behavioral research focused on social - environmental factors.

The study, which compared each model's success in Caucasian women with those of Asian descent (Chinese, Japanese, Filipino, Korean and Vietnamese), also raised important questions about the effect of race on cancer development: When Caucasian and Asian patients with similar family histories of breast and ovarian cancer were compared, the Asian women had higher rates of genetic mutation, although the rates of these cancers for Asians have traditionally been lower.

In a mouse model of triple - negative breast cancer, mice injected with cancer cells that over-express ZMYND11 had tumor volumes of less than 50 cubic millimeters while control mice and those injected with cells expressing ZMYND11 deficient for binding to the methyl group had tumor volumes ranging from 150 to 400 cubic millimeters at eight weeks.

Treatment in a mouse model of metastatic breast cancer with two of the down - regulated miRNAs (miR - 141 and miR - 219) suppressed bone metastases, suggesting that these miRNAs may have therapeutic utility.

Witt - Enderby at Duquesne is using her expertise in molecular pharmacology to study the effects of melatonin on a mouse breast cancer model.

Exploiting the same pre-clinical model used for their studies, the researchers are testing the efficacy of this kind of drug candidates against cancer stem cells, and the possibility of identifying combination regimens with standard chemotherapies with minimized toxic effects, with the perspective of their possible application for the treatment of human breast cancer.

A study combining tumor cells from patients with breast cancer with a laboratory model of blood vessel lining provides the most compelling evidence so far that a specific trio of cells is required for the spread of breast cancer.

In earlier studies involving animal models and human cancer cell lines, researchers found that breast cancer spreads when three specific cells are in direct contact: an endothelial cell (a type of cell that lines the blood vessels), a perivascular macrophage (a type of immune cell found near blood vessels), and a tumor cell that produces high levels of Mena, a protein that enhances a cancer cell's ability to spread.

«Our data confirmed that, while the rate of growth of triple - negative breast cancer was not affected by CDK 4/6 inhibitors, this class of drugs was able to significantly inhibit the spread of triple - negative breast cancer to distant organs when tested in multiple different triple - negative breast cancer models, including patient - derived xenografts.»

Until now, little was known in preclinical models about the mechanisms that allow breast cancer cells to leave the latent state and even less is known in patients,» explains Roger Gomis, head of the Growth Control and Cancer Metastasicancer cells to leave the latent state and even less is known in patients,» explains Roger Gomis, head of the Growth Control and Cancer MetastasiCancer Metastasis Lab.

To test this idea, the researchers utilized two mouse models of human breast cancer metastasis and found dormant disseminated tumor cells residing upon the membrane microvasculature of lung, bone marrow and brain tissue.

To determine whether endothelial cells — the cells that line the interior surface of blood vessels — directly influence breast cancer cell growth, they then created unique organotypic models of lung and bone marrow microvascular niches, in which endothelial cells formed blood vessel - like structures in culture as they would in the original organ.

Cheng, an assistant professor of medicine in hematology / oncology at Feinberg, provided the cell lines and NanoFlare targets the researchers used to model blood samples taken from breast cancer patients.

Dr. Narod, who is also a Tier 1 Canada Research Chair in Breast Cancer, recommends that doctors should consider adopting a standard model of care for all women diagnosed with advanced - stage ovarian cCancer, recommends that doctors should consider adopting a standard model of care for all women diagnosed with advanced - stage ovarian cancercancer:

In a four - year study conducted on the mouse model in advanced breast cancer metastasis in the eye's anterior chamber, Petty and colleagues found that the new nanoparticle not only killed tumor cells in the eye, but also extended the survival of experimental mice bearing 4T1 tumors, a cell line that is extremely difficult to kill.

Eran Andrechek, a physiology professor in the College of Human Medicine at Michigan State University, has discovered that many of the various models used in breast cancer research can replicate several characteristics of the human disease, especially at the gene level.

For example, the model estimated that there would be 493 cases of breast cancer over 306,298 person years among women with the lowest intake of red meat.

«New models of drug - resistant breast cancer point to better treatments.»

Using all the existing data that was available, Andrechek, along with MSU doctoral student Daniel Hollern, analyzed 1,172 mouse mammary tumor samples from 26 different preclinical models and was able to compile one of the largest databases to show which strains of mice were best suited to study a particular type of human breast cancer.

Human breast tumors transplanted into mice are excellent models of metastatic cancer and are providing insights into how to attack breast cancers that no longer respond to the drugs used to treat them, according to research from Washington University School of Medicine in St. Louis.

«This is the first example of taking a genetic sequence and designing a drug candidate that works effectively in an animal model against triple negative breast cancer,» said TSRI Professor Matthew Disney.